HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

Cervical Intraepithelial Neoplasia Grade II Clinical Trial

Official title:
A Phase I Open Label, Dose Escalation Clinical Trial Assessing the Safety, Tolerability, and Feasibility of pNGVL4aCRTE6E7L2 HPV DNA Vaccine Administration Via Intramuscular TriGridTM Electroporation Delivery System to Patients With HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia

Status Recruiting

Clinical Trial Summary

The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+ adult female subjects (≥ 19 years), with biopsy confirmed cervical intraepithelial (CIN) II or III that is human papillomavirus (HPV) 16+.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04131413
Study type	Interventional
Source	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Contact	Kimberly Levinson, MD
Phone	4109558240
Email	klevins1@jhmi.edu
Status	Recruiting
Phase	Phase 1
Start date	September 14, 2020
Completion date	September 30, 2024

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05210348` - Clinical Evaluation of Detection of High Risk HPV in Urine
	Active, not recruiting	`NCT05613283` - Primary Cervical Cancer Screening by Self-sampling HPV Test